Foghorn Therapeutics Advances Oncology Pipeline with Key Preclinical Data and Financial Runway
Event summary
- Foghorn's Phase 1 trial for FHD-909 (LY4050784) in NSCLC patients with SMARCA4 mutations is progressing on track.
- Preclinical data shows FHD-909 in combination with anti-PD-1 antibody drives complete, durable tumor regression.
- Selective CBP degrader FHT-171 and EP300 degrader programs show strong preclinical results, with INDs anticipated in 2027.
- Foghorn reports $184 million in cash, cash equivalents, and marketable securities, providing runway into the first half of 2028.
The big picture
Foghorn Therapeutics is advancing its Gene Traffic Control® Platform with promising preclinical data and strategic collaborations, positioning itself in the competitive oncology space. The company's strong financial position and pipeline progress reflect its focus on addressing unmet needs in difficult-to-treat cancers. The collaboration with Lilly underscores the potential of its lead program, FHD-909, in SMARCA4-mutated cancers.
What we're watching
- Clinical Trial Progress
- How the Phase 1 trial for FHD-909 will advance and whether it will meet the anticipated milestones.
- Pipeline Development
- The pace at which Foghorn's selective CBP and EP300 degrader programs will move towards IND filings.
- Financial Strategy
- Whether Foghorn's current cash runway will be sufficient to support its operations until potential revenue-generating milestones.
Related topics